PROCEPT BioRobotics Corporation (PRCT)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 4
Do Nothing: qualitativeScore is 2 (below the required floor of 3) with the shadow sum-gate flag false, so no entry is admissible despite a constructive chart — a momentum_breakout buy-stop above the settled 24.31 high (swingLow 22.55, buffer 0.27, stop 22.28, risk 1.58×ATR, targets 27.08/29.09, R/R 1.26) and an alternative pullback_to_support limit into the 23.14–22.55 shelf were both evaluated and would have cleared the structure, trend and R/R rules; both are blocked by the qualitative override, not by the setup.
Company overview
PROCEPT BioRobotics Corporation develops surgical robotic technologies focused on urology, notably the AquaBeam Robotic System for minimally invasive procedures. This system supports Aquablation therapy for treating benign prostatic hyperplasia.
Fundamental
fairPROCEPT BioRobotics shows strong revenue growth but faces profitability challenges and legal uncertainties.
Mixed fundamentals. A $352M TTM revenue base growing ~19% at a ~65% gross margin plus a net-cash balance sheet ($218M cash vs $77M debt, no maturities before October 2028, no going-concern or covenant issues) are offset by a $114.9M TTM net loss, -$85M TTM free cash flow, halved growth, SG&A and stock-based compensation outrunning revenue, a reaffirmed FY2026 guide that requires an outsized Q4, and a securities class action over handpiece sales, procedure volumes and guidance. Heavy insider buying near current prices and a wide DCF gap are the main offsets. Watchlist rather than conviction.
Sentiment
weakMedia sentiment has turned mildly negative following a Q3 earnings miss and ongoing legal issues.
The dominant near-term item is the 2026-11-04 Q3 2026 earnings print (confidence: announced), which the tape read as a miss — revenue $98.3M against a $100.5M FactSet estimate with a wider Zacks-adjusted loss and a larger net loss, only partly offset by reaffirmed FY2026 guidance and 22% U.S. procedure growth — and the media-sentiment delta is determinate and mildly negative (baseline +0.07 → scoring −0.09). The Red-Flag Screen found no severe flag but a moderate red-flag cap applied on confirmed material litigation with docket confirmation (securities class action filed 2026-07-24 plus a derivative action filed 2026-09-15), and retail sentiment is indeterminate because Reddit access was blocked (HTTP 403).
Technical
goodThe stock is in a confirmed short-term uptrend with strong momentum indicators.
PRCT is in a confirmed short-term uptrend: price 23.80 sits above SMA20 20.65, SMA50 19.52, SMA200 22.91, EMA9 22.32, EMA21 21.02 and daily VWAP 23.73, with MACD 1.16 > signal 0.75 > 0, an expanding histogram (0.26 → 0.41 over five sessions) and ADX 36.67 rising every session since 2026-11-02. Momentum is strong but stretched — RSI 69.03 and Williams %R −9.43 after a +13.9% six-session run from the 2026-10-30 low 18.90 to the 2026-11-12 high 24.31 — which caps the chart at a strong-setup-with-one-weak-signal grade rather than a 5. Volume confirms the advance (three-session regular-session dollar volume ≈ $21.6M, heaviest prints on up days) and there is no event risk inside the 15-day holding window. The structure is tradeable on its own terms — a buy-stop above the settled 24.31 high carries a structure-honest 22.28 stop (1.58×ATR) and R/R 1.26 — but the trade is not admissible: qualitativeScore is 2, below the required floor of 3, and the shadow sum-gate flag is false, so no production or paper entry is emitted.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

